Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

@article{Redon2012SafetyAE,
  title={Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).},
  author={Josep Redon and Giuseppe Mancia and Peter J. Sleight and Helmut Schumacher and Peggy Gao and Janice Pogue and Robert H. Fagard and Paolo Verdecchia and Michael D Weber and Michael B{\"o}hm and Bryan P Williams and Khalid Yusoff and Koon T Teo and Salim Yusuf},
  journal={Journal of the American College of Cardiology},
  year={2012},
  volume={59 1},
  pages={74-83}
}
OBJECTIVES We sought to determine whether the blood pressure (BP) levels at which cardiovascular (CV) protection is achieved differ between diabetic and nondiabetic patients from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). BACKGROUND Greater absolute benefits of BP reductions have been claimed for diabetic as compared with nondiabetic patients. METHODS A total of 25,584 patients (9,603 diabetic), older than 55 years, at high CV risk were… CONTINUE READING
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com